YCG LLC’s AbbVie ABBV Stock Holding History

YCG LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-4,800	Closed	-$314K	–	64
2014 Q4	$314K	Buy	+4,800	New	+$303K	0.1%	40

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

YCG LLC's ABBV Position: Q1 2015 in Review

YCG LLC sold out of AbbVie (ABBV) in Q1 2015, closing a stake of 4,800 shares — an estimated $314K sold.

YCG LLC first reported a position in ABBV in Q4 2014 and held it in 1 quarter. The position peaked at $314K in Q4 2014. 1,600 funds tracked by Wall St. Rank hold ABBV as of Q1 2015.

YCG LLC reported no remaining AbbVie position as of Q1 2015 after selling out during the quarter.
YCG LLC sold 4,800 AbbVie shares in Q1 2015, an estimated $314K.
YCG LLC first reported a position in AbbVie in Q4 2014 and held it in 1 quarter.
YCG LLC's AbbVie position peaked at $314K in Q4 2014.
1,600 funds tracked by Wall St. Rank held AbbVie as of Q1 2015.

Based on YCG LLC's 13F filing for Q1 2015, filed 7 May 2015.